Literature DB >> 28496862

Cost-Effectiveness of Atrial Fibrillation Ablation.

Gulmira Kudaiberdieva1, Bulent Gorenek1.   

Abstract

Atrial fibrillation (AF) is a frequently encountered rhythm disorder, characterized by high recurrence rate, frequent hospitalizations, reduced quality-of-life and increased the risk of mortality, heart failure and stroke. Along with these clinical complications this type of arrhythmia is the major driver of health-related expenditures. Radiofrequency catheter ablation (RFA) of atrial fibrillation has been shown to improve freedom from arrhythmia survival, reduce re-hospitalization rate and provide better quality-of-life as compared with rate control and rhythm control with antiarrhythmic therapy. Efficacy of AF ablation in terms of outcomes and costs has an evolving importance. In this review, we aimed to highlight current knowledge on AF ablation clinical outcomes based on results of randomized clinical trials and community-based studies, and overview how this improvement in clinical end-points affects costs for arrhythmia care and cost-effectiveness of AF ablation.

Entities:  

Keywords:  Atrial fibrillation; cost-effectiveness analysis; radiofrequency catheter ablation

Year:  2013        PMID: 28496862      PMCID: PMC5153071          DOI: 10.4022/jafib.880

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  50 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

3.  The burden of atrial fibrillation in the Netherlands.

Authors:  H E Heemstra; R Nieuwlaat; M Meijboom; H J Crijns
Journal:  Neth Heart J       Date:  2011-09       Impact factor: 2.380

4.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

5.  Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Louise S Jenkins; Michael Brodsky; Eleanor Schron; Mina Chung; Thomas Rocco; Ellis Lader; Martha Constantine; Robert Sheppard; Donald Holmes; Donna Mateski; Liz Floden; Marilyn Prasun; H Leon Greene; Lynn Shemanski
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

6.  Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Authors:  Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum
Journal:  Value Health       Date:  2006 Sep-Oct       Impact factor: 5.725

7.  Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.

Authors:  Joseph A Ladapo; Guy David; Candace L Gunnarsson; Steven C Hao; Sarah A White; Jamie L March; Matthew R Reynolds
Journal:  J Cardiovasc Electrophysiol       Date:  2011-07-21

Review 8.  Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis.

Authors:  Luca Testa; Giuseppe G L Biondi-Zoccai; Antonio Dello Russo; Fulvio Bellocci; Felicita Andreotti; Filippo Crea
Journal:  Eur Heart J       Date:  2005-05-04       Impact factor: 29.983

9.  [Cost-benefit analysis of concomitant atrial fibrillation management in Spain].

Authors:  María Jesús López Gude; Desiré Rodríguez Bezos; José Manuel Rodríguez Barrios
Journal:  Gac Sanit       Date:  2010 Jan-Feb       Impact factor: 2.139

10.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Authors:  David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

View more
  1 in total

1.  Economic evaluation of an ultra-high density mapping system compared to non-ultra-high density mapping systems for radiofrequency catheter ablation procedures in patients with atrial fibrillation.

Authors:  Bernardo Wise; Ramón Albarrán-Rincón; Alfonso De Lossada Juste; Ane Erkiaga Aio; Armin Klesius; Eliana Biundo; Edith Maes; Audrey Cordon; Pablo Ramos; Ignacio García-Bolao
Journal:  J Interv Card Electrophysiol       Date:  2021-02-06       Impact factor: 1.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.